{"id":398642,"date":"2020-12-13T21:12:40","date_gmt":"2020-12-14T02:12:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398642"},"modified":"2020-12-13T21:12:40","modified_gmt":"2020-12-14T02:12:40","slug":"senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">TAIPEI<\/span> and <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">Dec. 13, 2020<\/span> \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer<span id=\"spanHghlt86cc\">,\u00a0announced<\/span> their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral\/poster presentation at the upcoming\u00a0American Society of Clinical Oncology Gastrointestinal Cancers Symposium\u00a0(ASCO GI) in\u00a0San Francisco,\u00a015-17 January, 2021. Due to the <span id=\"spanHghltd11d\">COVID<\/span>-19 pandemic, the event will be hosted virtually.<\/p>\n<p>Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine\/Cisplatin compared to Gemcitabine\/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.\u00a0The trial met its primary endpoint at a pre-specified interim analysis demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) (P&lt;0.05), and was stopped early because superior efficacy was demonstrated. PFS was assessed by an independent statistician. <\/p>\n<p>The full abstract will be made available online via\u00a0<a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tv_slZTlC3TjL8t2HiwyPCeUTPWbisvgWeFnfz_M6DyA-GYst8MdPuIs-LAK-F2DMrdHMpNAFa8I82UmRrW2H4USc4rBtrQW3eSv9wlTZnbLJq1I1-_DLS46IgUWu-fJ\" rel=\"nofollow noopener noreferrer\">https:\/\/meetinglibrary.asco.org<\/a>\u00a0at\u00a05:00 PM (EST)\u00a0on\u00a011 January, 2021.<\/p>\n<p>\n        <b>More details of the CCA Treatment Abstract at the 2021 ASCO GI Symposium:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Abstract Title:\u00a0<\/b>Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib\/II study. <\/li>\n<li>\n          <b>Abstract Perm ID:\u00a0<\/b>312 <\/li>\n<li>\n          <b>Session Title:<\/b><br \/>\n          <b>\u00a0<\/b>Poster Highlights: Targeted Approaches and Multimodality <\/li>\n<li>\n          <b>Session Date and Time: <\/b>1\/17\/2021, <span class=\"xn-chron\">2:30 PM-3:15 PM (PST)<\/span><\/li>\n<\/ul>\n<p>\n        <b>About\u00a0Silmitasertib<\/b>\n      <\/p>\n<p>Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. Silmitasertib is safe and well-tolerated in humans.\u00a0 To date, three Phase I trials of Silmitasertib in cancer patients have been completed; currently, there is one ongoing Phase I and two ongoing Phase II studies.\u00a0In <span class=\"xn-chron\">December 2016<\/span>, Silmitasertib was granted Orphan Drug Designation by the U.S. FDA for the treatment of Cholangiocarcinoma. In <span class=\"xn-chron\">July 2020<\/span>, Silmitasertib was granted Rare Pediatric Disease Designation to treat Medulloblastoma by the U.S. FDA. An eIND was\u00a0granted by the U.S. FDA on <span class=\"xn-chron\">August 27, 2020<\/span>, to Dr. Rayyan at BUMCP to treat a patient with severe COVID-19. <\/p>\n<p>\n        <b>About Senhwa Biosciences<\/b>\n      <\/p>\n<p>Senhwa Biosciences, Inc. is a leading clinical-stage company focusing on developing first-in-class, next-generation DDR therapeutics for patients with unmet medical needs in oncology. Headquartered in <span class=\"xn-location\">Taiwan<\/span>, with an operational base in <span class=\"xn-location\">San Diego, California<\/span>, Senhwa is well-positioned to oversee the development of its compounds. Development is currently focused on two lead products: Silmitasertib (CX-4945) and Pidnarulex (CX-5461), both with novel mechanisms of action and for multiple indications. Clinical trials are ongoing in <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">United States<\/span>, Korea, and Taiwan.\u00a0<\/p>\n<p>Visit\u00a0Senhwa Biosciences for more details: <a target=\"_blank\" href=\"http:\/\/www.senhwabio.com\/\" rel=\"nofollow noopener noreferrer\">www.senhwabio.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium-301191717.html\">http:\/\/www.prnewswire.com\/news-releases\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium-301191717.html<\/a><\/p>\n<p>SOURCE  Senhwa Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=HK22403&amp;Transmission_Id=202012132108PR_NEWS_USPR_____HK22403&amp;DateId=20201213\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire TAIPEI and SAN DIEGO, Dec. 13, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer,\u00a0announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral\/poster presentation at the upcoming\u00a0American Society of Clinical Oncology Gastrointestinal Cancers Symposium\u00a0(ASCO GI) in\u00a0San Francisco,\u00a015-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted virtually. Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine\/Cisplatin compared to Gemcitabine\/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.\u00a0The trial met its primary endpoint at a pre-specified interim analysis demonstrating a statistically &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398642","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Senhwa Biosciences&#039;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senhwa Biosciences&#039;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TAIPEI and SAN DIEGO, Dec. 13, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer,\u00a0announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral\/poster presentation at the upcoming\u00a0American Society of Clinical Oncology Gastrointestinal Cancers Symposium\u00a0(ASCO GI) in\u00a0San Francisco,\u00a015-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted virtually. Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine\/Cisplatin compared to Gemcitabine\/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.\u00a0The trial met its primary endpoint at a pre-specified interim analysis demonstrating a statistically &hellip; Continue reading &quot;Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T02:12:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium\",\"datePublished\":\"2020-12-14T02:12:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/\"},\"wordCount\":455,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK22403&amp;sd=2020-12-13\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/\",\"name\":\"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK22403&amp;sd=2020-12-13\",\"datePublished\":\"2020-12-14T02:12:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK22403&amp;sd=2020-12-13\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK22403&amp;sd=2020-12-13\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","og_description":"PR Newswire TAIPEI and SAN DIEGO, Dec. 13, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer,\u00a0announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral\/poster presentation at the upcoming\u00a0American Society of Clinical Oncology Gastrointestinal Cancers Symposium\u00a0(ASCO GI) in\u00a0San Francisco,\u00a015-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted virtually. Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine\/Cisplatin compared to Gemcitabine\/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.\u00a0The trial met its primary endpoint at a pre-specified interim analysis demonstrating a statistically &hellip; Continue reading \"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T02:12:40+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium","datePublished":"2020-12-14T02:12:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/"},"wordCount":455,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/","name":"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13","datePublished":"2020-12-14T02:12:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK22403&amp;sd=2020-12-13"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Senhwa Biosciences&#8217;s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398642"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398642\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}